{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_15720", "batch_size": 260, "batch_pos": 59, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 2, "answer": "no", "rationale": "The segment reports stock movement; 'climbed' is not high-potency for threat impact.", "method": "llm_batch", "batch_id": "batch_2_12964", "batch_size": 260, "batch_pos": 42, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 3, "answer": "no", "rationale": "'climbed' relates to financial metrics, which are excluded from Q3.", "method": "llm_batch", "batch_id": "batch_3_17968", "batch_size": 260, "batch_pos": 236, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 4, "answer": "no", "rationale": "No loaded rhetorical question present.", "method": "llm_batch", "batch_id": "batch_4_15412", "batch_size": 260, "batch_pos": 232, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 5, "answer": "no", "rationale": "Reports factual information about stock climb after a report without explicit calming language or required tokens.", "method": "llm_batch", "batch_id": "batch_5_13160", "batch_size": 260, "batch_pos": 230, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
